Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1974 Oct;27(10):828–831. doi: 10.1136/jcp.27.10.828

Comparative activity of ampicillin and seven cephalosporins against group D streptococci

J M T Hamilton-Miller 1
PMCID: PMC475493  PMID: 4214839

Abstract

Minimum inhibitory concentrations have been determined for ampicillin and seven cephalosporins against 93 strains of group D streptococci isolated recently from clinical material. Ampicillin was much the most active compound (modal MIC = 1·6 μg/ml); cephaloridine, cephacetrile, and cefazolin had a modal MIC of 25 μg/ml, while corresponding figures for cephalothin, cephradine, cephalexin, and cefoxitin were 50, 100, 200, and 800 μg/ml, respectively. Thus, none of the newer cephalosporins is an improvement in respect to activity against enterococci over existing compounds, and ampicillin remains overwhelmingly the β-lactam antibiotic of choice for the treatment of infections by such organisms. Pharmacokinetic considerations, however, indicate that certain cephalosporins, for instance, cephaloridine, cefazolin, and cephanone, may be worthy of further study in view of possible synergy with aminoglycoside antibiotics.

Full text

PDF
828

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Axelrod J., Meyers B. R., Hirschman S. Z. Cephapirin: in vitro antibacterial spectrum. Appl Microbiol. 1971 Nov;22(5):904–908. doi: 10.1128/am.22.5.904-908.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Axelrod J., Meyers B. R., Hirschman S. Z. Cephapirin: pharmacology in normal human volunteers. J Clin Pharmacol New Drugs. 1972 Feb-Mar;12(2):84–88. doi: 10.1002/j.1552-4604.1972.tb00150.x. [DOI] [PubMed] [Google Scholar]
  3. Facklam R. R., Moody M. D. Presumptive identification of group D streptococci: the bile-esculin test. Appl Microbiol. 1970 Aug;20(2):245–250. doi: 10.1128/am.20.2.245-250.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hamilton-Miller J. M., Brumfitt W. Newer beta-lactam antibiotics. Infection. 1974;2(2):82–94. doi: 10.1007/BF01642027. [DOI] [PubMed] [Google Scholar]
  5. Hodges G. R., Scholand J. F., Perkins R. L. Cephacetrile: clinical evaluation in 27 patients. Antimicrob Agents Chemother. 1973 Feb;3(2):228–234. doi: 10.1128/aac.3.2.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Isenberg H. D., Painter B. G., Sampson-Scherer J., Siegel M. Clinical laboratory study of cephacetrile and cephalothin against bacteria recently isolated from clinical specimens. Am J Clin Pathol. 1973 May;59(5):700–705. doi: 10.1093/ajcp/59.5.700. [DOI] [PubMed] [Google Scholar]
  7. KLEIN J. O., EICKHOFF T. C., TILLES J. G., FINLAND M. CEPHALOTHIN: ACTIVITY IN VITRO, ABSORPTION AND EXCRETION IN NORMAL SUBJECTS AND CLINICAL OBSERVATIONS IN 40 PATIENTS. Am J Med Sci. 1964 Dec;248:640–656. [PubMed] [Google Scholar]
  8. Kosmidis J., Hamilton-Miller J. M., Gilchrist J. N., Kerry D. W., Brumfitt W. Cefoxitin, a new semi-synthetic cephamycin: an in-vitro and in-vivo comparison with cephalothin. Br Med J. 1973 Dec 15;4(5893):653–655. doi: 10.1136/bmj.4.5893.653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Meyers B. R., Hirschman S. Z., Nicholas P. Cephanone: in vitro antibacterial activity and pharmacology in normal human volunteers. Antimicrob Agents Chemother. 1972 Oct;2(4):250–254. doi: 10.1128/aac.2.4.250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Neiss E. S. Cephradine--a summary of preclinical studies and clinical pharmacology. J Ir Med Assoc. 1973 Mar 24;Suppl:1–12. [PubMed] [Google Scholar]
  11. Seneca H. Drug susceptibility-resistance pattern of gram-negative uropathogens to seven cephalosporins. Am J Med Sci. 1973 Nov;266(5):381–385. doi: 10.1097/00000441-197311000-00005. [DOI] [PubMed] [Google Scholar]
  12. Simon H. J. Antimicrobial susceptibility of group D hemolytic streptococci (enterococci). Am J Med Sci. 1967 Jan;253(1):14–18. doi: 10.1097/00000441-196701000-00004. [DOI] [PubMed] [Google Scholar]
  13. Standiford H. D., De Maine J. B., Kirby W. M. Antibiotic synergism of enterococci. Relation to inhibitory concentrations. Arch Intern Med. 1970 Aug;126(2):255–259. [PubMed] [Google Scholar]
  14. Toala P., McDonald A., Wilcox C., Finland M. Susceptibility of group D streptococcus (enterococcus) to 21 antibiotics in vitro, with special reference to species differences. Am J Med Sci. 1969 Dec;258(6):416–430. doi: 10.1097/00000441-196912000-00006. [DOI] [PubMed] [Google Scholar]
  15. Turck M., Belcher D. W., Ronald A., Smith R. H., Wallace J. F. New cephalosporin antibiotic--cephaloridine. Clinical and laboratory evaluation. Arch Intern Med. 1967 Jan;119(1):50–59. doi: 10.1001/archinte.119.1.50. [DOI] [PubMed] [Google Scholar]
  16. Zaki A., Schreiber E. C., Weliky I., Knill J. R., Hubsher J. A. Clinical pharmacology of oral cephradine. J Clin Pharmacol. 1974 Feb-Mar;14(2):118–126. doi: 10.1002/j.1552-4604.1974.tb02301.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES